The Truth About Retatrutide: The Underground Peptide Market
Retatrutide is being promoted across TikTok, social media and online peptide markets—but what are consumers actually buying?
In this investigative healthcare video, AJ Pakpour examines the retatrutide gold rush, research peptides labeled “not for human consumption,” questionable purity claims and the difference between clinical research and products being sold online.
What is retatrutide?
Retatrutide, also known as LY3437943, is an investigational triple agonist developed by Eli Lilly. It targets the GLP-1, GIP and glucagon receptors. Retatrutide is not currently FDA approved or commercially available as a prescription medication.
This video explores:
• What retatrutide is and how it works
• Retatrutide clinical trials and weight-loss research
• Research peptides and online peptide vendors
• Certificates of analysis and “99% purity” claims
• Sterility, identity and dosing concerns
• Retatrutide compared with semaglutide and tirzepatide
• What consumers should understand before trusting online claims
For independent retatrutide research, clinical-trial information, safety updates and regulatory analysis, visit:
https://trytrutide.com
Created and presented by AJ Pakpour, healthcare entrepreneur, author and founder of TryTrutide.
Educational content only. Retatrutide is investigational and not FDA approved. This video does not provide medical advice or recommend purchasing or using research peptides.
Keywords: retatrutide, retatrutide explained, what is retatrutide, LY3437943, retatrutide weight loss, retatrutide clinical trials, retatrutide FDA approval, research peptides, peptide safety, triple agonist, GLP-1, GIP, glucagon, semaglutide, tirzepatide, Eli Lilly, AJ Pakpour, TryTrutide